Search

Your search keyword '"Obeid E"' showing total 211 results
Start Over Author "Obeid E"
211 results on '"Obeid E"'

1. Rotavirus and adenovirus in children evaluated for viral gastroenteritis at a single healthcare center in the Eastern Province of Saudi Arabia: A perspective of two decades

Author

Ahmed K Alqurayn, Obeid E. Obeid, and Khaled R. Alkharsah

Subjects
adenovirus, antigen test, rotavirus, saudi arabia, viral gastroenteritis, Public aspects of medicine, RA1-1270
Abstract

BACKGROUND: The aim of this study was to determine the distribution of rotavirus and adenovirus in pediatric patients evaluated for viral gastroenteritis in a hospital in the Eastern Province of Saudi Arabia for 22 years. MATERIALS AND METHODS: This was a retrospective study based in a secondary healthcare center in Saudi Arabia. Laboratory and demographic data were collected from hospital records for all pediatric patients (up to 14 years old) evaluated for viral gastroenteritis by rotavirus/adenovirus antigen detection kit from January 2000 to December 2022. Data were analyzed utilizing SPSS version 28.0. Categorical data were presented as frequency and percentages, whereas mean and standard deviations were computed for continuous variables. Chi-square test and t-test were used to determine statistical significance. RESULTS: The overall yields of antigen detection were 13.6% for rotavirus and 2.6% for adenovirus. Coinfection with both viruses was documented in 0.5% of the study population. Rotavirus was persistently detected in the past two decades with varying frequency, but the detection of adenovirus showed intervals of at least three consecutive years of zero confirmed cases. Before 2013, when the rotavirus vaccine was introduced in Saudi Arabia, rotavirus was much more prevalent than adenovirus (30% compared to 3.8% in 2010), but they became equally prevalent a decade after the introduction of the vaccine. Rotavirus gastroenteritis showed three different peaks in the year, in March, July, and December. Each peak was followed by a gradual decrease in prevalence before the next peak. Adenovirus, in contrast, was detected consistently around the year at rates between 2% and 5%. CONCLUSION: Rotavirus and adenovirus gastroenteritis have changed in prevalence in the past two decades. We found distinct seasonal patterns associated with rotavirus and adenovirus gastroenteritis. The utilization of virological testing for pediatric gastroenteritis with syndromic testing panels is to be encouraged to improve the knowledge of the true prevalence of enteric viruses.

Published
2024
Full Text
View/download PDF

2. Seropositivity of syphilis among individuals screened in a tertiary hospital in the Eastern Province of Saudi Arabia

Author

Nahid H. O. Wanni, Reem Al Dossary, Obeid E. Obeid, Nourah Hasan Al Qahtani, Zaheenul Islam Siddiqui, Ayman A. El-Badry, and Khaled R. Alkharsah

Subjects
Medicine
Abstract

BACKGROUND: Sexually transmitted infections are a serious public health problem. Syphilis, a multistage, curable chronic disease caused by the spirochete Treponema pallidum, remains a major health problem worldwide. The disease re-emerged in the era of HIV in many countries despite the accessibility of curative therapy and continuing public health efforts to eliminate it. OBJECTIVE: Analyse the seropositivity for syphilis. DESIGN: Retrospective cross-sectional. SETTING: Tertiary hospital. PATIENTS AND METHODS: We retrospectively studied individuals who underwent screening tests for syphilis between January 2014 and December 2018. The samples that were positive by both screening and confirmatory tests were considered as confirmed positive for syphilis. MAIN OUTCOME MEASURES: Syphilis positivity identified by chemiluminescence immunoassay, the rapid plasma reagin test, and specific antibodies against Treponema pallidum. SAMPLE SIZE: 11 832. RESULTS: Of the 11 832, 54 (0.45%) were confirmed as seropositive for syphilis. Thirty-three (61.1%) were non-Saudi; 21 (38.9%) were Saudis. Thirty (55.6%) cases were males. Twenty-two (40.74%) were married and 29 (53.70%) were unmarried. Of the 54 diagnosed as syphilis positive, 28 (51.9%) were expatriate workers screened for pre-employment. The percentage of syphilis among Saudis was 0.36%. In an overall chi-square analysis, a P

Published
2021
Full Text
View/download PDF

3. Association between hepatitis C virus viremia and the rs12979860, rs2228145 and rs1800795 SNP (CT/AC/GG) genotype in Saudi kidney transplant recipients

Author

Khaled R Alkharsah, Alhussain J Alzahrani, Obeid E Obeid, Reem Y Aljindan, Adnane Guella, Amein K Al-Ali, Hussain R Al-Turaifi, and Talal A Sallam

Subjects
hepatitis c virus, interleukin-28b, interleukin-6, kidney transplant, saudi arabia, Medicine
Abstract

Background: Hepatitis C virus (HCV) is a major health problem, particularly in high-risk groups such as kidney transplant recipients, where it can adversely affect graft survival and increase the relative risk for mortality. Recently, the role of genetic variation among HCV patients in determining the outcome of infections has been under investigation. Objective: To investigate the association of single-nucleotide polymorphisms (SNPs) rs12979860 (located within the interleukin-28B locus), rs2228145 (interleukin-6 receptor) and rs1800795 (interleukin-6 promoter) with HCV viremia in renal transplant patients. Materials and Methods: In this analytical cross-sectional study, 149 kidney transplant recipients, 82 males (median age: 41 years) and 67 females (median age: 45 years), were screened for HCV RNA in blood using real-time polymerase chain reaction and genotyped by sequencing (rs12979860) and restriction fragment length polymorphism (rs2228145 and rs1800795). Results: HCV RNA was detected in 17 (11.41%) of the 149 patients. There was no statistically significant association between the studied SNPs and HCV viremia. However, a combination of the CT/AC/GG genotype was significantly associated with HCV viremia (odds ratio: 5.4). The genotype AA of rs2228145 in the IL-6 receptor was associated with viremia levels of >105 copies/ml (odds ratio: 5.96). Conclusion: To the best of the authors' knowledge, this is the first study that has shown that the CT/AC/GG genotype has an impact on HCV viremia in kidney transplant patients. Therefore, such SNP genotypes may potentially be used to identify transplant patients at risk of HCV infection.

Published
2020
Full Text
View/download PDF

4. Characterization of human rotavirus subgroups and serotypes in children under five with acute gastroenteritis in a Saudi Hospital

Author

Obeid E Obeid

Subjects
Immunochromatography, rotavirus, subgroup, serotypes, Public aspects of medicine, RA1-1270
Abstract

Objectives: Rotavirus is the most common cause of severe diarrhea in children. Currently, there is no published data on the prevalence of subgroups and serotypes of rotavirus in the Eastern province of Saudi Arabia. The objectives of the present study were to assess the rotavirus infection in children with acute gastroenteritis and to assess the subgroups and serotypes of rotavirus in the Children and Maternity Hospital in Dammam, Eastern Saudi Arabia. Materials and Methods: Children under 5 years of age with gastroenteritis attending the emergency rooms, or hospitalized in the pediatric wards of in the Children and Maternity Hospital in Dammam were included in the study (N=156). Laboratory diagnosis of rotavirus shedding was established using the novel rotavirus STAT-PAK immunochromatographical test. Subgroup and G-serotype of the positive stool specimens were analyzed by the ELISA method. Results and Conclusions: Using the novel immmunochromatographic assay, 37 samples were shown to be positive for rotavirus (23.7%). Subgroup I (serotype 2) was found to constitute 5.4% of the isolates and subgroup II (serotypes 1, 3 and 4) was found to constitute 56.7% of the isolates, whereas 37.8% were non-typeable. A survey of serotypes of rotavirus in the whole region as well as in the whole of Saudi Arabia will provide important information about the subgroups and groups of rotavirus in the community and may help in assessing the success of the rotavirus vaccine in the future.

Published
2011
Full Text
View/download PDF

5. Prevalence of herpes simplex virus types 1 and 2 and associated sociodemographic variables in pregnant women attending King Fahd Hospital of the university

Author

Obeid E Obeid

Subjects
HSV-1, HSV-2, pregnant women, IgG, IgM, sociodemographic variables., Public aspects of medicine, RA1-1270
Abstract

Objectives: The risk factors associated with herpes simplex virus (HSV) seropositivity in pregnant women in Saudi Arabia are not known. This study was aimed at identifying the sociodemographic variables associated with seroprevalence of HSV-1 and HSV-2 in pregnant women in a Saudi hospital. Materials and Methods: This is a hospital-based cross-sectional study that included all pregnant mothers who delivered at King Fahd Hospital of the University (KFHU) over a period of two years (November 2002 to October 2004). Anti-HSV-1 and anti-HSV-2 IgG and IgM antibodies were determined using type-specific ELISA. Each subject completed a structured questionnaire. Relevant sociodemographic variables were analyzed. Results: A higher prevalence of HSV-1 IgG antibodies (93.2%) was found in those mothers who were not educated (illiterate or read and write only) in comparison with pregnant women with formal school education (p = 0.021). This was confirmed by using multiple regression analysis (p = 0.027). The prevalence of HSV-2 IgG was higher among civil servants and teachers (40.0 % and 14.7 % respectively) than in unskilled labourers, professionals, or housewives (p = 0.0001). Using multiple regression analysis, the prevalence of HSV-2 IgG was found to increase in older mothers (p = 0.037). No statistically significant association was found between HSV seroprevalence and other socio demographic variables. Conclusions: Identifying the sociodemographic factors associated with HSV infection will help in understanding the epidemiology of HSV infection in Saudi women and may help in designing preventive measures.

Published
2007

6. Lack of MERS Coronavirus Neutralizing Antibodies in Humans, Eastern Province, Saudi Arabia

Author

Stefanie Gierer, Heike Hofmann-Winkler, Waleed H. Albuali, Stephanie Bertram, Abdullah M. Al-Rubaish, Abdullah A. Yousef, Awatif N. Al-Nafaie, Amein K. Al-Ali, Obeid E. Obeid, Khaled R. Alkharsah, and Stefan Pöhlmann

Subjects
MERS coronavirus, neutralizing antibodies, Saudi Arabia, spike, pseudotyping, MERS-CoV, Medicine, Infectious and parasitic diseases, RC109-216
Abstract

We used a lentiviral vector bearing the viral spike protein to detect neutralizing antibodies against Middle East respiratory syndrome coronavirus (MERS-CoV) in persons from the Eastern Province of Saudi Arabia. None of the 268 samples tested displayed neutralizing activity, which suggests that MERS-CoV infections in humans are infrequent in this province.

Published
2013
Full Text
View/download PDF

7. Analysis of hepatitis C virus infection among sickle cell anemia patients by an antigen-antibody combination assay

Author

Obeid E. Obeid and Alhusain J. Alzahrani

Subjects
Hepatitis C virus, Hepatitis B virus, sickle cell anemia, antigen-antibody assay, Microbiology, QR1-502
Abstract

Hepatitis C virus (HCV) has a major impact on public health. In spite of the progress made in the prevention of transfusion-transmitted infections over the last years, these still occur, especially in multi-transfused patients such as sickle cell anemia patients. Sickle cell disease (SCD) is highly prevalent in Eastern Saudi Arabia. Little is known about the prevalence of HCV in Saudi sickle cell disease patients. The present study aimed to assess HCV and HBV antigens, antibodies and viral genome among sickle cell anemia patients in a tertiary hospital in Eastern Saudi Arabia. Methods used included measurement of HCV antigen and antibodies using the novel HCV antigen/antibody combination assay, assessment of HCV core antigen and measurement of viral genome using standard commercial kits. Of the 138 sickle cell disease samples tested, 5 (3.6%) samples gave positive results. Their hemoglobin ranged between 7.8 and 10.1 g/dL, their erythrocyte count ranged between 3.1¥106 and 3.9¥106. Out of these 5 samples, 4 were also positive by the HCV Core Ag assay and by the HCV RNA PCR test (80%). None of the control group was positive. Seven patients were positive for HBs antibodies. One sample was positive for HBsAg, and this indicates chronic carrier state. Improving the testing for blood-borne infections such as HCV and HBV will result in better control of these infections in sickle cell disease patients which will inevitably lead to lower mortality and morbidity in this group of patients.

Published
2011
Full Text
View/download PDF

9. Susceptibility to Rubella Infection and Incidence of Congenital Rubella Infection: 6 Years Retrospective Study

Author

Reem A Al Dossary, Sarah Althuwaiqeb, Khaled R Alkharsah, Nahid HO Wanni, Basavaraja C Hunasemaranda, Obeid E Obeid, Zaheenul Islam Siddiqui, Ayman A El-Badry, and Nourah Hasan Al Qahtani

Subjects
International Journal of General Medicine, General Medicine
Abstract

Reem A Al Dossary,1 Sarah Althuwaiqeb,2 Khaled R Alkharsah,1 Nahid HO Wanni,1 Basavaraja C Hunasemaranda,1 Obeid E Obeid,1 Zaheenul Islam Siddiqui,1 Ayman A El-Badry,1 Nourah Hasan Al Qahtani3 1Department of Microbiology, College of Medicine, Imam Abdulrahman bin Faisal University, Dammam, Saudi Arabia; 2Imam Abdulrahman bin Faisal University, Dammam, Saudi Arabia; 3Department of Obstetrics and Gynecology, College of Medicine, Imam Abdulrahman bin Faisal University, Dammam, Saudi ArabiaCorrespondence: Reem A Al Dossary, Email raaldossary@iau.edu.saIntroduction: Rubella is considered one of the most serious and most common congenital infections. Despite global efforts for elimination, rubella cases are still being reported in many parts of the world. The purpose of this study is to determine the level of immunity to rubella in the community and most importantly among women at childbearing age in the eastern province of Saudi Arabia and compare it with the target set by the World Health Organization (WHO) along with the incidence of acute rubella infection and the associated congenital rubella infection and congenital rubella syndrome.Methods: This is a retrospective cross-sectional study over the six years period (Jan 2014–Jun 2020) on all individuals tested for rubella IgM and IgG in a university teaching hospital.Results: Nighty one percent (15,894/17,469) of the population tested showed evidence of rubella immunity with 8.8% (1546/17,469) being susceptible. Among women at childbearing age, susceptibility to rubella was higher with 9.2% (1220/13,278) of women showing no evidence of immunity. In addition, acute rubella infection was reported for 0.17% (29/17,469) of the population tested and 0.15% (20/13,278) in women at childbearing age. No cases of congenital rubella infection were reported in the study period.Discussion: The level of Rubella immunity in the population is 91% and is less than the WHO target for rubella control therefore, risk of resurge of cases is present, indicating the need for continued national surveillance and more efforts to improve vaccination coverage in the kingdom.Keywords: rubella, immunity, susceptibility, congenital

Published
2022
Full Text
View/download PDF

13. Seropositivity of syphilis among individuals screened in a tertiary hospital in the Eastern Province of Saudi Arabia

Author

Nourah H. Al Qahtani, Reem Al Dossary, Nahid H. O. Wanni, Ayman A. El-Badry, Zaheenul Islam Siddiqui, Obeid E. Obeid, and Khaled R. Alkharsah

Subjects
Male, medicine.medical_specialty, 030231 tropical medicine, Saudi Arabia, lcsh:Medicine, Tertiary Care Centers, 03 medical and health sciences, 0302 clinical medicine, Seroepidemiologic Studies, medicine, Humans, Syphilis, 030212 general & internal medicine, Retrospective Studies, Treponema, biology, business.industry, Public health, lcsh:R, General Medicine, biology.organism_classification, medicine.disease, Cross-Sectional Studies, Chronic disease, Family medicine, Original Article, business
Abstract

BACKGROUND: Sexually transmitted infections are a serious public health problem. Syphilis, a multistage, curable chronic disease caused by the spirochete Treponema pallidum , remains a major health problem worldwide. The disease re-emerged in the era of HIV in many countries despite the accessibility of curative therapy and continuing public health efforts to eliminate it. OBJECTIVE: Analyse the seropositivity for syphilis. DESIGN: Retrospective cross-sectional. SETTING: Tertiary hospital. PATIENTS AND METHODS: We retrospectively studied individuals who underwent screening tests for syphilis between January 2014 and December 2018. The samples that were positive by both screening and confirmatory tests were considered as confirmed positive for syphilis. MAIN OUTCOME MEASURES: Syphilis positivity identified by chemiluminescence immunoassay, the rapid plasma reagin test, and specific antibodies against Treponema pallidum . SAMPLE SIZE: 11 832. RESULTS: Of the 11 832, 54 (0.45%) were confirmed as seropositive for syphilis. Thirty-three (61.1%) were non-Saudi; 21 (38.9%) were Saudis. Thirty (55.6%) cases were males. Twenty-two (40.74%) were married and 29 (53.70%) were unmarried. Of the 54 diagnosed as syphilis positive, 28 (51.9%) were expatriate workers screened for pre-employment. The percentage of syphilis among Saudis was 0.36%. In an overall chi-square analysis, a P P =.004) and Sudanese ( P =.005) differed significantly from other nationalities. CONCLUSION: The study showed that syphilis was low among the screened population. More than half of the syphilis positive cases in this study were household employees. Screening for syphilis assists in planning complementary services for target populations and improves syphilis control. LIMITATIONS: Retrospective design. Hospital-based findings may not be representative of the seroprevalence of syphilis in the general population. CONFLICT OF INTEREST: None.

Published
2021
Full Text
View/download PDF

14. Susceptibility to Rubella Infection and Incidence of Congenital Rubella Infection: 6 Years Retrospective Study

Author

Al Dossary,Reem A, Althuwaiqeb,Sarah, Alkharsah,Khaled R, Wanni,Nahid HO, Hunasemaranda,Basavaraja C, Obeid,Obeid E, Siddiqui,Zaheenul Islam, El-Badry,Ayman A, Al Qahtani,Nourah Hasan, Al Dossary,Reem A, Althuwaiqeb,Sarah, Alkharsah,Khaled R, Wanni,Nahid HO, Hunasemaranda,Basavaraja C, Obeid,Obeid E, Siddiqui,Zaheenul Islam, El-Badry,Ayman A, and Al Qahtani,Nourah Hasan

Abstract

Reem A Al Dossary,1 Sarah Althuwaiqeb,2 Khaled R Alkharsah,1 Nahid HO Wanni,1 Basavaraja C Hunasemaranda,1 Obeid E Obeid,1 Zaheenul Islam Siddiqui,1 Ayman A El-Badry,1 Nourah Hasan Al Qahtani3 1Department of Microbiology, College of Medicine, Imam Abdulrahman bin Faisal University, Dammam, Saudi Arabia; 2Imam Abdulrahman bin Faisal University, Dammam, Saudi Arabia; 3Department of Obstetrics and Gynecology, College of Medicine, Imam Abdulrahman bin Faisal University, Dammam, Saudi ArabiaCorrespondence: Reem A Al Dossary, Email raaldossary@iau.edu.saIntroduction: Rubella is considered one of the most serious and most common congenital infections. Despite global efforts for elimination, rubella cases are still being reported in many parts of the world. The purpose of this study is to determine the level of immunity to rubella in the community and most importantly among women at childbearing age in the eastern province of Saudi Arabia and compare it with the target set by the World Health Organization (WHO) along with the incidence of acute rubella infection and the associated congenital rubella infection and congenital rubella syndrome.Methods: This is a retrospective cross-sectional study over the six years period (Jan 2014–Jun 2020) on all individuals tested for rubella IgM and IgG in a university teaching hospital.Results: Nighty one percent (15,894/17,469) of the population tested showed evidence of rubella immunity with 8.8% (1546/17,469) being susceptible. Among women at childbearing age, susceptibility to rubella was higher with 9.2% (1220/13,278) of women showing no evidence of immunity. In addition, acute rubella infection was reported for 0.17% (29/17,469) of the population tested and 0.15% (20/13,278) in women at childbearing age. No cases of congenital rubella infection were reported in the study period.Discussion: The level of Rubella immunity in the population is 91% and is less than the WHO target for rubella control therefore, risk of resurge of cases

Published
2022

16. Association between Hepatitis C Virus Viremia and the rs12979860, rs2228145 and rs1800795 SNP (CT/AC/GG) Genotype in Saudi Kidney Transplant Recipients

Author

Talal A. Sallam, Adnane Guella, Al-Hussain J. Alzahrani, Reem Aljindan, Amein K. Al-Ali, Obeid E. Obeid, Khaled R. Alkharsah, and Hussain R Al-Turaifi

Subjects
kidney transplant, medicine.medical_specialty, Hepatitis C virus, Saudi Arabia, lcsh:Medicine, Single-nucleotide polymorphism, Viremia, medicine.disease_cause, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Genotype, medicine, SNP, 030212 general & internal medicine, business.industry, interleukin-6, lcsh:R, virus diseases, General Medicine, Odds ratio, medicine.disease, interleukin-28B, Interleukin 28B, 030220 oncology & carcinogenesis, Relative risk, Original Article, business
Abstract

Background: Hepatitis C virus (HCV) is a major health problem, particularly in high-risk groups such as kidney transplant recipients, where it can adversely affect graft survival and increase the relative risk for mortality. Recently, the role of genetic variation among HCV patients in determining the outcome of infections has been under investigation. Objective: To investigate the association of single-nucleotide polymorphisms (SNPs) rs12979860 (located within the interleukin-28B locus), rs2228145 (interleukin-6 receptor) and rs1800795 (interleukin-6 promoter) with HCV viremia in renal transplant patients. Materials and Methods: In this analytical cross-sectional study, 149 kidney transplant recipients, 82 males (median age: 41 years) and 67 females (median age: 45 years), were screened for HCV RNA in blood using real-time polymerase chain reaction and genotyped by sequencing (rs12979860) and restriction fragment length polymorphism (rs2228145 and rs1800795). Results: HCV RNA was detected in 17 (11.41%) of the 149 patients. There was no statistically significant association between the studied SNPs and HCV viremia. However, a combination of the CT/AC/GG genotype was significantly associated with HCV viremia (odds ratio: 5.4). The genotype AA of rs2228145 in the IL-6 receptor was associated with viremia levels of >105 copies/ml (odds ratio: 5.96). Conclusion: To the best of the authors' knowledge, this is the first study that has shown that the CT/AC/GG genotype has an impact on HCV viremia in kidney transplant patients. Therefore, such SNP genotypes may potentially be used to identify transplant patients at risk of HCV infection.

Published
2019

18. Susceptibility to Rubella Infection and Incidence of Congenital Rubella Infection: 6 Years Retrospective Study.

Author

Dossary, Reem A Al, Althuwaiqeb, Sarah, Alkharsah, Khaled R, Wanni, Nahid HO, Hunasemaranda, Basavaraja C, Obeid, Obeid E, Siddiqui, Zaheenul Islam, El-Badry, Ayman A, and Qahtani, Nourah Hasan Al

Subjects
RUBELLA, CONGENITAL disorders, CHILDBEARING age, HERD immunity, VACCINATION coverage, TEACHING hospitals
Abstract

Introduction: Rubella is considered one of the most serious and most common congenital infections. Despite global efforts for elimination, rubella cases are still being reported in many parts of the world. The purpose of this study is to determine the level of immunity to rubella in the community and most importantly among women at childbearing age in the eastern province of Saudi Arabia and compare it with the target set by the World Health Organization (WHO) along with the incidence of acute rubella infection and the associated congenital rubella infection and congenital rubella syndrome. Methods: This is a retrospective cross-sectional study over the six years period (Jan 2014–Jun 2020) on all individuals tested for rubella IgM and IgG in a university teaching hospital. Results: Nighty one percent (15,894/17,469) of the population tested showed evidence of rubella immunity with 8.8% (1546/17,469) being susceptible. Among women at childbearing age, susceptibility to rubella was higher with 9.2% (1220/13,278) of women showing no evidence of immunity. In addition, acute rubella infection was reported for 0.17% (29/17,469) of the population tested and 0.15% (20/13,278) in women at childbearing age. No cases of congenital rubella infection were reported in the study period. Discussion: The level of Rubella immunity in the population is 91% and is less than the WHO target for rubella control therefore, risk of resurge of cases is present, indicating the need for continued national surveillance and more efforts to improve vaccination coverage in the kingdom. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

22. Lack of MERS coronavirus neutralizing antibodies in humans, eastern province, Saudi Arabia

Author

Gierer, Stefanie, Hofmann-Winkler, Heike, Albuali, Waleed H., Bertram, Stephanie, Rubaish, Abdullah M. Al-, Yousef, Abdullah A., Nafaie, Awatif N. Al-, Ali, Amein K. Al-, Obeid, Obeid E., Alkharsah, Khaled R., and Pohlmann, Stefan

Subjects
Viral antibodies -- Health aspects, Infection -- Health aspects, Antibodies -- Health aspects, Health, World Health Organization
Abstract

The emergence of the Middle East respiratory syndrome coronavirus (MERS-CoV, formerly termed EMC coronavirus [1]) could pose a serious threat to public health (2). As of September 2013, a total [...]

Published
2013
Full Text
View/download PDF

24. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers.

Author

Teixeira M.R., Rhiem K., Izatt L., Tripathi V., Cardoso M., Foulkes W.D., Aprikian A., van Randeraad H., Davidson R., Longmuir M., Ruijs M.W.G., Adank M., Williams R., Andrews L., Murphy D.G., Halliday D., Walker L., Liljegren A., Carlsson S., Azzabi A., Jobson I., Morton C., Shackleton K., Snape K., Hanson H., Harris M., Tischkowitz M., Taylor A., Kirk J., Susman R., Chen-Shtoyerman R., Spigelman A., Pachter N., Ahmed M., Ramon y Cajal T., Zgajnar J., Brewer C., Gadea N., Brady A.F., van Os T., Gallagher D., Johannsson O., Donaldson A., Barwell J., Nicolai N., Friedman E., Obeid E., Greenhalgh L., Murthy V., Copakova L., Saya S., McGrath J., Cooke P., Ronlund K., Richardson K., Henderson A., Teo S.H., Arun B., Kast K., Dias A., Aaronson N.K., Ardern-Jones A., Bangma C.H., Castro E., Dearnaley D., Eccles D.M., Tricker K., Eyfjord J., Falconer A., Foster C., Gronberg H., Hamdy F.C., Stefansdottir V., Khoo V., Lindeman G.J., Lubinski J., Axcrona K., Mikropoulos C., Mitra A., Moynihan C., Rennert G., Suri M., Wilson P., Dudderidge T., Offman J., Kote-Jarai Z., Vickers A., Lilja H., Eeles R.A., Helderman van den Enden A.T.J.M., Page E.C., Bancroft E.K., Brook M.N., Assel M., Hassan Al Battat M., Thomas S., Taylor N., Chamberlain A., Pope J., Raghallaigh H.N., Evans D.G., Rothwell J., Maehle L., Grindedal E.M., James P., Mascarenhas L., McKinley J., Side L., Thomas T., van Asperen C., Vasen H., Kiemeney L.A., Ringelberg J., Jensen T.D., Osther P.J.S., Helfand B.T., Genova E., Oldenburg R.A., Cybulski C., Wokolorczyk D., Ong K.-R., Huber C., Lam J., Taylor L., Salinas M., Feliubadalo L., Oosterwijk J.C., van Zelst-Stams W., Cook J., Rosario D.J., Domchek S., Powers J., Buys S., O'Toole K., Ausems M.G.E.M., Schmutzler R.K., Teixeira M.R., Rhiem K., Izatt L., Tripathi V., Cardoso M., Foulkes W.D., Aprikian A., van Randeraad H., Davidson R., Longmuir M., Ruijs M.W.G., Adank M., Williams R., Andrews L., Murphy D.G., Halliday D., Walker L., Liljegren A., Carlsson S., Azzabi A., Jobson I., Morton C., Shackleton K., Snape K., Hanson H., Harris M., Tischkowitz M., Taylor A., Kirk J., Susman R., Chen-Shtoyerman R., Spigelman A., Pachter N., Ahmed M., Ramon y Cajal T., Zgajnar J., Brewer C., Gadea N., Brady A.F., van Os T., Gallagher D., Johannsson O., Donaldson A., Barwell J., Nicolai N., Friedman E., Obeid E., Greenhalgh L., Murthy V., Copakova L., Saya S., McGrath J., Cooke P., Ronlund K., Richardson K., Henderson A., Teo S.H., Arun B., Kast K., Dias A., Aaronson N.K., Ardern-Jones A., Bangma C.H., Castro E., Dearnaley D., Eccles D.M., Tricker K., Eyfjord J., Falconer A., Foster C., Gronberg H., Hamdy F.C., Stefansdottir V., Khoo V., Lindeman G.J., Lubinski J., Axcrona K., Mikropoulos C., Mitra A., Moynihan C., Rennert G., Suri M., Wilson P., Dudderidge T., Offman J., Kote-Jarai Z., Vickers A., Lilja H., Eeles R.A., Helderman van den Enden A.T.J.M., Page E.C., Bancroft E.K., Brook M.N., Assel M., Hassan Al Battat M., Thomas S., Taylor N., Chamberlain A., Pope J., Raghallaigh H.N., Evans D.G., Rothwell J., Maehle L., Grindedal E.M., James P., Mascarenhas L., McKinley J., Side L., Thomas T., van Asperen C., Vasen H., Kiemeney L.A., Ringelberg J., Jensen T.D., Osther P.J.S., Helfand B.T., Genova E., Oldenburg R.A., Cybulski C., Wokolorczyk D., Ong K.-R., Huber C., Lam J., Taylor L., Salinas M., Feliubadalo L., Oosterwijk J.C., van Zelst-Stams W., Cook J., Rosario D.J., Domchek S., Powers J., Buys S., O'Toole K., Ausems M.G.E.M., and Schmutzler R.K.

Abstract

Background: Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2 mutations. Objective(s): To report the utility of PSA screening, PrCa incidence, positive predictive value of PSA, biopsy, and tumour characteristics after 3 yr of screening, by BRCA status. Design, setting, and participants: Men aged 40-69 yr with a germline pathogenic BRCA1/2 mutation and male controls testing negative for a familial BRCA1/2 mutation were recruited. Participants underwent PSA screening for 3 yr, and if PSA > 3.0 ng/ml, men were offered prostate biopsy. Outcome measurements and statistical analysis: PSA levels, PrCa incidence, and tumour characteristics were evaluated. Statistical analyses included Poisson regression offset by person-year follow-up, chi-square tests for proportion t tests for means, and Kruskal-Wallis for medians. Results and limitations: A total of 3027 patients (2932 unique individuals) were recruited (919 BRCA1 carriers, 709 BRCA1 noncarriers, 902 BRCA2 carriers, and 497 BRCA2 noncarriers). After 3 yr of screening, 527 men had PSA > 3.0 ng/ml, 357 biopsies were performed, and 112 PrCa cases were diagnosed (31 BRCA1 carriers, 19 BRCA1 noncarriers, 47 BRCA2 carriers, and 15 BRCA2 noncarriers). Higher compliance with biopsy was observed in BRCA2 carriers compared with noncarriers (73% vs 60%). Cancer incidence rate per 1000 person years was higher in BRCA2 carriers than in noncarriers (19.4 vs 12.0; p = 0.03); BRCA2 carriers were diagnosed at a younger age (61 vs 64 yr; p = 0.04) and were more likely to have clinically significant disease than BRCA2 noncarriers (77% vs 40%; p = 0.01). No differences in age or tumour characteristics were detected between BRCA1 carriers and BRCA1 noncarriers. The 4 kallikrein marker model discriminated better (area under the curve [AUC] = 0.73) for clinically significant cancer at

Published
2019

25. Psychosocial impact of undergoing prostate cancer screening for men with BRCA1 or BRCA2 mutations

Author

Bancroft, EK, Saya, S, Page, EC, Myhill, K, Thomas, S, Pope, J, Chamberlain, A, Hart, R, Glover, W, Cook, J, Rosario, DJ, Helfand, BT, Selkirk, CH, Davidson, R, Longmuir, M, Eccles, DM, Gadea, N, Brewer, C, Barwell, J, Salinas, M, Greenhalgh, L, Tischkowitz, M, Henderson, A, Evans, DG, Buys, SS, Eeles, RA, Aaronson, NK, Eeles, R, Bancroft, E, Page, E, Kote-Jarai, Z, Ardern-Jones, A, Bangma, C, Castro, E, Dearnaley, D, Falconer, A, Foster, C, Gronberg, H, Hamdy, FC, Johannsson, OT, Khoo, V, Eccles, D, Lilja, H, Evans, G, Eyfjord, J, Lubinski, J, Maehle, L, Mikropoulos, C, Millner, A, Mitra, A, Offman, J, Moynihan, C, Rennert, G, Suri, M, Dias, A, Taylor, N, D'Mello, L, James, P, Mitchell, G, Shanley, S, Richardson, K, McKinley, J, Petelin, L, Murphy, M, Mascarenhas, L, Murphy, D, Lam, J, Taylor, L, Miller, C, Stapleton, A, Chong, M, Suthers, G, Poplawski, N, Tucker, K, Andrews, L, Duffy, J, Millard, R, Ward, R, Williams, R, Stricker, P, Kirk, J, Bowman, M, Patel, M, Harris, M, O'Connell, S, Hunt, C, Smyth, C, Frydenberg, M, Lindeman, G, Shackleton, K, Morton, C, Susman, R, McGaughran, J, Boon, M, Pachter, N, Townshend, S, Schofield, L, Nicholls, C, Spigelman, A, Gleeson, M, Amor, D, Burke, J, Patterson, B, Swindle, P, Scott, R, Foulkes, W, Boshari, T, Aprikian, A, Jensen, T, Bojeson, A, Osther, P, Skytte, A-B, Cruger, D, Tondering, MK, Gerdes, A-M, Schmutzler, R, Rhiem, K, Wihler, P, Kast, K, Griebsch, C, Johannsson, O, Stefansdottir, V, Murthy, V, Sarin, R, Awatagiri, K, Ghonge, S, Kowtal, P, Mulgund, G, Gallagher, D, Bambury, R, Farrell, M, Gallagher, F, Kiernan, I, Friedman, E, Chen-Shtoyerman, R, Basevitch, A, Leibovici, D, Melzer, E, Ben-Yehoshua, SJ, Nicolai, N, Radice, P, Valdagni, R, Magnani, T, Gay, S, Teo, SH, Tan, HM, Yoon, S-Y, Thong, MK, Vasen, H, Ringleberg, J, van Asperen, C, Kiemeney, B, van Zelst-Stams, W, Ausems, MGEM, van der Luijt, RB, van Os, T, Ruijs, MWG, Adank, MA, Oldenburg, RA, Helderman-van den Enden, APTJM, Caanen, BAH, Oosterwijk, JC, Moller, P, Brennhovd, B, Medvik, H, Hanslien, E, Grindedal, EM, Cybulski, C, Wokolorczyk, D, Teixeira, M, Maia, S, Peixoto, A, Henrique, R, Oliveira, J, Goncalves, N, Araujo, L, Seixas, M, Souto, JP, Nogueira, P, Copakova, L, Zgajnar, J, Krajc, M, Vrecar, A, Capella, G, Ramon y Cajal, T, Fisas, D, Mora, J, Esquena, S, Balmana, J, Morote, J, Liljegren, A, Hjalm-Eriksson, M, Ekdahl, K-J, Carlsson, S, George, A, Kemp, Z, Wiggins, J, Moss, C, Van As, N, Thompson, A, Ogden, C, Woodhouse, C, Kumar, P, Bulman, B, Rothwell, J, Tricker, K, Wise, G, Mercer, C, McBride, D, Costello, P, Pearce, A, Torokwa, A, Paterson, J, Clowes, V, Taylor, A, Newcombe, B, Walker, L, Halliday, D, Stayner, B, Fleming-Brown, D, Snape, K, Hanson, H, Hodgson, S, Brice, G, Homfray, T, Hammond, C, Kohut, K, Anjum, U, Dearing, A, Mencias, M, Potter, A, Renton, C, Searle, A, Hill, K, Goodman, S, Garcia, L, Devlin, G, Everest, S, Nadolski, M, Douglas, F, Jobson, I, Paez, E, Donaldson, A, Tomkins, S, Langman, C, Jacobs, C, Pichert, G, Shaw, A, Kulkarni, A, Tripathi, V, Rose, S, Compton, C, Watson, M, Reinholtz, C, Brady, A, Dorkins, H, Melville, A, Kosicka-Slawinska, M, Cummings, C, Kiesel, V, Bartlett, M, Randhawa, K, Ellery, N, Side, L, Male, A, Simon, K, Rees, K, Tidey, L, Gurasashvili, J, Nevitt, L, Ingram, S, Howell, A, Rosario, D, Catto, J, Howson, J, Ong, K-R, Chapman, C, Cole, T, Heaton, T, Hoffman, J, Burgess, L, Huber, C, Islam, F, Watt, C, Duncan, A, Kockelbergh, R, Mzazi, S, Dineen, A, Sattar, A, Kaemba, B, Sidat, Z, Patel, N, Siguake, K, Birt, A, Poultney, U, Umez-Eronini, N, Mom, J, Sutton, V, Cornford, P, Bermingham, N, Yesildag, P, Treherne, K, Griffiths, J, Cogley, L, Gott, H, Rubinstein, WS, Hulick, P, McGuire, M, Shevrin, D, Kaul, K, Weissman, S, Newlin, A, Vogel, K, Weiss, S, Hook, N, Buys, S, Goldgar, D, Conner, T, Venne, V, Stephenson, R, Dechet, C, Domchek, S, Powers, J, Rustgi, N, Strom, S, Arun, B, Davis, JW, Yamamura, Y, Obeid, E, Giri, V, Gross, L, Bealin, L, Cooney, K, Stoffel, E, Okoth, L, Bancroft, EK, Saya, S, Page, EC, Myhill, K, Thomas, S, Pope, J, Chamberlain, A, Hart, R, Glover, W, Cook, J, Rosario, DJ, Helfand, BT, Selkirk, CH, Davidson, R, Longmuir, M, Eccles, DM, Gadea, N, Brewer, C, Barwell, J, Salinas, M, Greenhalgh, L, Tischkowitz, M, Henderson, A, Evans, DG, Buys, SS, Eeles, RA, Aaronson, NK, Eeles, R, Bancroft, E, Page, E, Kote-Jarai, Z, Ardern-Jones, A, Bangma, C, Castro, E, Dearnaley, D, Falconer, A, Foster, C, Gronberg, H, Hamdy, FC, Johannsson, OT, Khoo, V, Eccles, D, Lilja, H, Evans, G, Eyfjord, J, Lubinski, J, Maehle, L, Mikropoulos, C, Millner, A, Mitra, A, Offman, J, Moynihan, C, Rennert, G, Suri, M, Dias, A, Taylor, N, D'Mello, L, James, P, Mitchell, G, Shanley, S, Richardson, K, McKinley, J, Petelin, L, Murphy, M, Mascarenhas, L, Murphy, D, Lam, J, Taylor, L, Miller, C, Stapleton, A, Chong, M, Suthers, G, Poplawski, N, Tucker, K, Andrews, L, Duffy, J, Millard, R, Ward, R, Williams, R, Stricker, P, Kirk, J, Bowman, M, Patel, M, Harris, M, O'Connell, S, Hunt, C, Smyth, C, Frydenberg, M, Lindeman, G, Shackleton, K, Morton, C, Susman, R, McGaughran, J, Boon, M, Pachter, N, Townshend, S, Schofield, L, Nicholls, C, Spigelman, A, Gleeson, M, Amor, D, Burke, J, Patterson, B, Swindle, P, Scott, R, Foulkes, W, Boshari, T, Aprikian, A, Jensen, T, Bojeson, A, Osther, P, Skytte, A-B, Cruger, D, Tondering, MK, Gerdes, A-M, Schmutzler, R, Rhiem, K, Wihler, P, Kast, K, Griebsch, C, Johannsson, O, Stefansdottir, V, Murthy, V, Sarin, R, Awatagiri, K, Ghonge, S, Kowtal, P, Mulgund, G, Gallagher, D, Bambury, R, Farrell, M, Gallagher, F, Kiernan, I, Friedman, E, Chen-Shtoyerman, R, Basevitch, A, Leibovici, D, Melzer, E, Ben-Yehoshua, SJ, Nicolai, N, Radice, P, Valdagni, R, Magnani, T, Gay, S, Teo, SH, Tan, HM, Yoon, S-Y, Thong, MK, Vasen, H, Ringleberg, J, van Asperen, C, Kiemeney, B, van Zelst-Stams, W, Ausems, MGEM, van der Luijt, RB, van Os, T, Ruijs, MWG, Adank, MA, Oldenburg, RA, Helderman-van den Enden, APTJM, Caanen, BAH, Oosterwijk, JC, Moller, P, Brennhovd, B, Medvik, H, Hanslien, E, Grindedal, EM, Cybulski, C, Wokolorczyk, D, Teixeira, M, Maia, S, Peixoto, A, Henrique, R, Oliveira, J, Goncalves, N, Araujo, L, Seixas, M, Souto, JP, Nogueira, P, Copakova, L, Zgajnar, J, Krajc, M, Vrecar, A, Capella, G, Ramon y Cajal, T, Fisas, D, Mora, J, Esquena, S, Balmana, J, Morote, J, Liljegren, A, Hjalm-Eriksson, M, Ekdahl, K-J, Carlsson, S, George, A, Kemp, Z, Wiggins, J, Moss, C, Van As, N, Thompson, A, Ogden, C, Woodhouse, C, Kumar, P, Bulman, B, Rothwell, J, Tricker, K, Wise, G, Mercer, C, McBride, D, Costello, P, Pearce, A, Torokwa, A, Paterson, J, Clowes, V, Taylor, A, Newcombe, B, Walker, L, Halliday, D, Stayner, B, Fleming-Brown, D, Snape, K, Hanson, H, Hodgson, S, Brice, G, Homfray, T, Hammond, C, Kohut, K, Anjum, U, Dearing, A, Mencias, M, Potter, A, Renton, C, Searle, A, Hill, K, Goodman, S, Garcia, L, Devlin, G, Everest, S, Nadolski, M, Douglas, F, Jobson, I, Paez, E, Donaldson, A, Tomkins, S, Langman, C, Jacobs, C, Pichert, G, Shaw, A, Kulkarni, A, Tripathi, V, Rose, S, Compton, C, Watson, M, Reinholtz, C, Brady, A, Dorkins, H, Melville, A, Kosicka-Slawinska, M, Cummings, C, Kiesel, V, Bartlett, M, Randhawa, K, Ellery, N, Side, L, Male, A, Simon, K, Rees, K, Tidey, L, Gurasashvili, J, Nevitt, L, Ingram, S, Howell, A, Rosario, D, Catto, J, Howson, J, Ong, K-R, Chapman, C, Cole, T, Heaton, T, Hoffman, J, Burgess, L, Huber, C, Islam, F, Watt, C, Duncan, A, Kockelbergh, R, Mzazi, S, Dineen, A, Sattar, A, Kaemba, B, Sidat, Z, Patel, N, Siguake, K, Birt, A, Poultney, U, Umez-Eronini, N, Mom, J, Sutton, V, Cornford, P, Bermingham, N, Yesildag, P, Treherne, K, Griffiths, J, Cogley, L, Gott, H, Rubinstein, WS, Hulick, P, McGuire, M, Shevrin, D, Kaul, K, Weissman, S, Newlin, A, Vogel, K, Weiss, S, Hook, N, Buys, S, Goldgar, D, Conner, T, Venne, V, Stephenson, R, Dechet, C, Domchek, S, Powers, J, Rustgi, N, Strom, S, Arun, B, Davis, JW, Yamamura, Y, Obeid, E, Giri, V, Gross, L, Bealin, L, Cooney, K, Stoffel, E, and Okoth, L

Abstract

OBJECTIVES: To report the baseline results of a longitudinal psychosocial study that forms part of the IMPACT study, a multi-national investigation of targeted prostate cancer (PCa) screening among men with a known pathogenic germline mutation in the BRCA1 or BRCA2 genes. PARTICPANTS AND METHODS: Men enrolled in the IMPACT study were invited to complete a questionnaire at collaborating sites prior to each annual screening visit. The questionnaire included sociodemographic characteristics and the following measures: the Hospital Anxiety and Depression Scale (HADS), Impact of Event Scale (IES), 36-item short-form health survey (SF-36), Memorial Anxiety Scale for Prostate Cancer, Cancer Worry Scale-Revised, risk perception and knowledge. The results of the baseline questionnaire are presented. RESULTS: A total of 432 men completed questionnaires: 98 and 160 had mutations in BRCA1 and BRCA2 genes, respectively, and 174 were controls (familial mutation negative). Participants' perception of PCa risk was influenced by genetic status. Knowledge levels were high and unrelated to genetic status. Mean scores for the HADS and SF-36 were within reported general population norms and mean IES scores were within normal range. IES mean intrusion and avoidance scores were significantly higher in BRCA1/BRCA2 carriers than in controls and were higher in men with increased PCa risk perception. At the multivariate level, risk perception contributed more significantly to variance in IES scores than genetic status. CONCLUSION: This is the first study to report the psychosocial profile of men with BRCA1/BRCA2 mutations undergoing PCa screening. No clinically concerning levels of general or cancer-specific distress or poor quality of life were detected in the cohort as a whole. A small subset of participants reported higher levels of distress, suggesting the need for healthcare professionals offering PCa screening to identify these risk factors and offer additional information and support t

Published
2019

26. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers

Author

Page, EC, Bancroft, EK, Brook, MN, Assel, M, Al Battat, MH, Thomas, S, Taylor, N, Chamberlain, A, Pope, J, Ni Raghallaigh, H, Evans, DG, Rothwell, J, Maehle, L, Grindedal, EM, James, P, Mascarenhas, L, McKinley, J, Side, L, Thomas, T, van Asperen, C, Vasen, H, Kiemeney, LA, Ringelberg, J, Jensen, TD, Osther, PJS, Helfand, BT, Genova, E, Oldenburg, RA, Cybulski, C, Wokolorczyk, D, Ong, K-R, Huber, C, Lam, J, Taylor, L, Salinas, M, Feliubadalo, L, Oosterwijk, JC, van Zelst-Stams, W, Cook, J, Rosario, DJ, Domchek, S, Powers, J, Buys, S, O'Toole, K, Ausems, MGEM, Schmutzler, RK, Rhiem, K, Izatt, L, Tripathi, V, Teixeira, MR, Cardoso, M, Foulkes, WD, Aprikian, A, van Randeraad, H, Davidson, R, Longmuir, M, Ruijs, MWG, Helderman van den Enden, ATJM, Adank, M, Williams, R, Andrews, L, Murphy, DG, Halliday, D, Walker, L, Liljegren, A, Carlsson, S, Azzabi, A, Jobson, I, Morton, C, Shackleton, K, Snape, K, Hanson, H, Harris, M, Tischkowitz, M, Taylor, A, Kirk, J, Susman, R, Chen-Shtoyerman, R, Spigelman, A, Pachter, N, Ahmed, M, Ramon y Cajal, T, Zgajnar, J, Brewer, C, Gadea, N, Brady, AF, van Os, T, Gallagher, D, Johannsson, O, Donaldson, A, Barwell, J, Nicolai, N, Friedman, E, Obeid, E, Greenhalgh, L, Murthy, V, Copakova, L, Saya, S, McGrath, J, Cooke, P, Ronlund, K, Richardson, K, Henderson, A, Teo, SH, Arun, B, Kast, K, Dias, A, Aaronson, NK, Ardern-Jones, A, Bangma, CH, Castro, E, Dearnaley, D, Eccles, DM, Tricker, K, Eyfjord, J, Falconer, A, Foster, C, Gronberg, H, Hamdy, FC, Stefansdottir, V, Khoo, V, Lindeman, GJ, Lubinski, J, Axcrona, K, Mikropoulos, C, Mitra, A, Moynihan, C, Rennert, G, Suri, M, Wilson, P, Dudderidge, T, Offman, J, Kote-Jarai, Z, Vickers, A, Lilja, H, Eeles, RA, Page, EC, Bancroft, EK, Brook, MN, Assel, M, Al Battat, MH, Thomas, S, Taylor, N, Chamberlain, A, Pope, J, Ni Raghallaigh, H, Evans, DG, Rothwell, J, Maehle, L, Grindedal, EM, James, P, Mascarenhas, L, McKinley, J, Side, L, Thomas, T, van Asperen, C, Vasen, H, Kiemeney, LA, Ringelberg, J, Jensen, TD, Osther, PJS, Helfand, BT, Genova, E, Oldenburg, RA, Cybulski, C, Wokolorczyk, D, Ong, K-R, Huber, C, Lam, J, Taylor, L, Salinas, M, Feliubadalo, L, Oosterwijk, JC, van Zelst-Stams, W, Cook, J, Rosario, DJ, Domchek, S, Powers, J, Buys, S, O'Toole, K, Ausems, MGEM, Schmutzler, RK, Rhiem, K, Izatt, L, Tripathi, V, Teixeira, MR, Cardoso, M, Foulkes, WD, Aprikian, A, van Randeraad, H, Davidson, R, Longmuir, M, Ruijs, MWG, Helderman van den Enden, ATJM, Adank, M, Williams, R, Andrews, L, Murphy, DG, Halliday, D, Walker, L, Liljegren, A, Carlsson, S, Azzabi, A, Jobson, I, Morton, C, Shackleton, K, Snape, K, Hanson, H, Harris, M, Tischkowitz, M, Taylor, A, Kirk, J, Susman, R, Chen-Shtoyerman, R, Spigelman, A, Pachter, N, Ahmed, M, Ramon y Cajal, T, Zgajnar, J, Brewer, C, Gadea, N, Brady, AF, van Os, T, Gallagher, D, Johannsson, O, Donaldson, A, Barwell, J, Nicolai, N, Friedman, E, Obeid, E, Greenhalgh, L, Murthy, V, Copakova, L, Saya, S, McGrath, J, Cooke, P, Ronlund, K, Richardson, K, Henderson, A, Teo, SH, Arun, B, Kast, K, Dias, A, Aaronson, NK, Ardern-Jones, A, Bangma, CH, Castro, E, Dearnaley, D, Eccles, DM, Tricker, K, Eyfjord, J, Falconer, A, Foster, C, Gronberg, H, Hamdy, FC, Stefansdottir, V, Khoo, V, Lindeman, GJ, Lubinski, J, Axcrona, K, Mikropoulos, C, Mitra, A, Moynihan, C, Rennert, G, Suri, M, Wilson, P, Dudderidge, T, Offman, J, Kote-Jarai, Z, Vickers, A, Lilja, H, and Eeles, RA

Abstract

BACKGROUND: Mutations in BRCA2 cause a higher risk of early-onset aggressive prostate cancer (PrCa). The IMPACT study is evaluating targeted PrCa screening using prostate-specific-antigen (PSA) in men with germline BRCA1/2 mutations. OBJECTIVE: To report the utility of PSA screening, PrCa incidence, positive predictive value of PSA, biopsy, and tumour characteristics after 3 yr of screening, by BRCA status. DESIGN, SETTING, AND PARTICIPANTS: Men aged 40-69 yr with a germline pathogenic BRCA1/2 mutation and male controls testing negative for a familial BRCA1/2 mutation were recruited. Participants underwent PSA screening for 3 yr, and if PSA > 3.0 ng/ml, men were offered prostate biopsy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: PSA levels, PrCa incidence, and tumour characteristics were evaluated. Statistical analyses included Poisson regression offset by person-year follow-up, chi-square tests for proportion t tests for means, and Kruskal-Wallis for medians. RESULTS AND LIMITATIONS: A total of 3027 patients (2932 unique individuals) were recruited (919 BRCA1 carriers, 709 BRCA1 noncarriers, 902 BRCA2 carriers, and 497 BRCA2 noncarriers). After 3 yr of screening, 527 men had PSA > 3.0 ng/ml, 357 biopsies were performed, and 112 PrCa cases were diagnosed (31 BRCA1 carriers, 19 BRCA1 noncarriers, 47 BRCA2 carriers, and 15 BRCA2 noncarriers). Higher compliance with biopsy was observed in BRCA2 carriers compared with noncarriers (73% vs 60%). Cancer incidence rate per 1000 person years was higher in BRCA2 carriers than in noncarriers (19.4 vs 12.0; p = 0.03); BRCA2 carriers were diagnosed at a younger age (61 vs 64 yr; p = 0.04) and were more likely to have clinically significant disease than BRCA2 noncarriers (77% vs 40%; p = 0.01). No differences in age or tumour characteristics were detected between BRCA1 carriers and BRCA1 noncarriers. The 4 kallikrein marker model discriminated better (area under the curve [AUC] = 0.73) for clinically significant cancer at

Published
2019

27. Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition (vol 118, pg 266, 2018)

Author

Mikropoulos, C., Selkirk, C.G.H., Saya, S., Bancroft, E., Vertosick, E., Dadaev, T., Brendler, C., Page, E., Dias, A., Evans, D.G., Rothwell, J., Maehle, L., Axcrona, K., Richardson, K., Eccles, D., Jensen, T., Osther, P.J., Asperen, C.J. van, Vasen, H., Kiemeney, L.A., Ringelberg, J., Cybulski, C., Wokolorczyk, D., Hart, R., Glover, W., Lam, J., Taylor, L., Salinas, M., Feliubadalo, L., Oldenburg, R., Cremers, R., Verhaegh, G., Zelst-Stams, W.A. van, Oosterwijk, J.C., Cook, J., Rosario, D.J., Buys, S.S., Conner, T., Domchek, S., Powers, J., Ausems, M.G.E.M., Teixeira, M.R., Maia, S., Izatt, L., Schmutzler, R., Rhiem, K., Foulkes, W.D., Boshari, T., Davidson, R., Ruijs, M., Helderman-van den Enden, A.T.J.M., Andrews, L., Walker, L., Snape, K., Henderson, A., Jobson, I., Lindeman, G.J., Liljegren, A., Harris, M., Adank, M.A., Kirk, J., Taylor, A., Susman, R., Chen-Shtoyerman, R., Pachter, N., Spigelman, A., Side, L., Zgajnar, J., Mora, J., Brewer, C., Gadea, N., Brady, A.F., Gallagher, D., Os, T. van, Donaldson, A., Stefansdottir, V., Barwell, J., James, P.A., Murphy, D., Friedman, E., Nicolai, N., Greenhalgh, L., Obeid, E., Murthy, V., Copakova, L., McGrath, J., Teo, S.H., Strom, S., Kast, K., Leongamornlert, D.A., Chamberlain, A., Pope, J., Newlin, A.C., Aaronson, N., Ardern-Jones, A., Bangma, C., Castro, E., Dearnaley, D., Eyfjord, J., Falconer, A., Foster, C.S., Gronberg, H., Hamdy, F.C., Johannsson, O., Khoo, V., Lubinski, J., Grindedal, E.M., McKinley, J., Shackleton, K., Mitra, A.V., Moynihan, C., Rennert, G., Suri, M., Tricker, K., Moss, S., Kote-Jarai, Z., Vickers, A., Lilja, H., Helfand, B.T., Eeles, R.A., and IMPACT Study Collaborators

Published
2018

28. Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition

Author

Mikropoulos, C., Selkirk, C.G.H., Saya, S., Bancroft, E., Vertosick, E., Dadaev, T., Brendler, C., Page, E., Dias, A., Evans, D.G., Rothwell, J., Maehle, L., Axcrona, K., Richardson, K., Eccles, D., Jensen, T., Osther, P.J., Asperen, C.J. van, Vasen, H., Kiemeney, L.A., Ringelberg, J., Cybulski, C., Wokolorczyk, D., Hart, R., Glover, W., Lam, J., Taylor, L., Salinas, M., Feliubadalo, L., Oldenburg, R., Cremers, R., Verhaegh, G., Zelst-Stams, W.A. van, Oosterwijk, J.C., Cook, J., Rosario, D.J., Buys, S.S., Conner, T., Domchek, S., Powers, J., Ausems, M.G.E.M., Teixeira, M.R., Maia, S., Izatt, L., Schmutzler, R., Rhiem, K., Foulkes, W.D., Boshari, T., Davidson, R., Ruijs, M., Helderman-van den Enden, A.T.J.M., Andrews, L., Walker, L., Snape, K., Henderson, A., Jobson, I., Lindeman, G.J., Liljegren, A., Harris, M., Adank, M.A., Kirk, J., Taylor, A., Susman, R., Chen-Shtoyerman, R., Pachter, N., Spigelman, A., Side, L., Zgajnar, J., Mora, J., Brewer, C., Gadea, N., Brady, A.F., Gallagher, D., Os, T. van, Donaldson, A., Stefansdottir, V., Barwell, J., James, P.A., Murphy, D., Friedman, E., Nicolai, N., Greenhalgh, L., Obeid, E., Murthy, V., Copakova, L., McGrath, J., Teo, S.H., Strom, S., Kast, K., Leongamornlert, D.A., Chamberlain, A., Pope, J., Newlin, A.C., Aaronson, N., Ardern-Jones, A., Bangma, C., Castro, E., Dearnaley, D., Eyfjord, J., Falconer, A., Foster, C.S., Gronberg, H., Hamdy, F.C., Johannsson, O., Khoo, V., Lubinski, J., Grindedal, E.M., McKinley, J., Shackleton, K., Mitra, A.V., Moynihan, C., Rennert, G., Suri, M., Tricker, K., Moss, S., Kote-Jarai, Z., Vickers, A., Lilja, H., Helfand, B.T., Eeles, R.A., and IMPACT Study Collaborators

Subjects
predictive model, prostate cancer, BRCA1, urologic and male genital diseases, genetic predisposition, BRCA2, PSA velocity
Abstract

Background: Prostate-specific antigen (PSA) and PSA-velocity (PSAV) have been used to identify men at risk of prostate cancer (PrCa). The IMPACT study is evaluating PSA screening in men with a known genetic predisposition to PrCa due to BRCA1/2 mutations. This analysis evaluates the utility of PSA and PSAV for identifying PrCa and high-grade disease in this cohort. Methods: PSAV was calculated using logistic regression to determine if PSA or PSAV predicted the result of prostate biopsy (PB) in men with elevated PSA values. Cox regression was used to determine whether PSA or PSAV predicted PSA elevation in men with low PSAs. Interaction terms were included in the models to determine whether BRCA status influenced the predictiveness of PSA or PSAV. Results: 1634 participants had >= 3 PSA readings of whom 174 underwent PB and 45 PrCas diagnosed. In men with PSA >3.0 ng ml(-1), PSAV was not significantly associated with presence of cancer or high-grade disease. PSAV did not add to PSA for predicting time to an elevated PSA. When comparing BRCA1/2 carriers to non-carriers, we found a significant interaction between BRCA status and last PSA before biopsy (P = 0.031) and BRCA2 status and PSAV (P = 0.024). However, PSAV was not predictive of biopsy outcome in BRCA2 carriers. Conclusions: PSA is more strongly predictive of PrCa in BRCA carriers than non-carriers. We did not find evidence that PSAV aids decision-making for BRCA carriers over absolute PSA value alone.

Published
2018

31. Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition.

Author

Izatt L., Davidson R., Ruijs M., Helderman-Van Den Enden A.T., Andrews L., Walker L., Snape K., Henderson A., Jobson I., Lindeman G.J., Liljegren A., Harris M., Adank M.A., Kirk J., Taylor A., Susman R., Chen-Shtoyerman R., Pachter N., Spigelman A., Side L., Zgajnar J., Mora J., Brewer C., Gadea N., Brady A.F., Gallagher D., Van Os T., Donaldson A., Stefansdottir V., Barwell J., James P.A., Murphy D., Friedman E., Nicolai N., Greenhalgh L., Obeid E., Murthy V., Copakova L., McGrath J., Teo S.-H., Strom S., Kast K., Leongamornlert D.A., Chamberlain A., Pope J., Newlin A.C., Aaronson N., Ardern-Jones A., Bangma C., Castro E., Dearnaley D., Eyfjord J., Falconer A., Foster C.S., Gronberg H., Hamdy F.C., Johannsson O., Khoo V., Lubinski J., Grindedal E.M., McKinley J., Shackleton K., Mitra A.V., Moynihan C., Rennert G., Suri M., Tricker K., Moss S., Kote-Jarai Z., Vickers A., Lilja H., Helfand B.T., Eeles R.A., Mikropoulos C., Selkirk C.G.H., Saya S., Bancroft E., Vertosick E., Dadaev T., Brendler C., Page E., Dias A., Evans D.G., Rothwell J., Maehle L., Axcrona K., Richardson K., Eccles D., Jensen T., Osther P.J., Van Asperen C.J., Vasen H., Kiemeney L.A., Ringelberg J., Cybulski C., Wokolorczyk D., Hart R., Glover W., Lam J., Taylor L., Salinas M., Feliubadalo L., Oldenburg R., Cremers R., Verhaegh G., Van Zelst-Stams W.A., Oosterwijk J.C., Cook J., Rosario D.J., Buys S.S., Conner T., Domchek S., Powers J., Ausems M.G., Teixeira M.R., Maia S., Schmutzler R., Rhiem K., Foulkes W.D., Boshari T., Izatt L., Davidson R., Ruijs M., Helderman-Van Den Enden A.T., Andrews L., Walker L., Snape K., Henderson A., Jobson I., Lindeman G.J., Liljegren A., Harris M., Adank M.A., Kirk J., Taylor A., Susman R., Chen-Shtoyerman R., Pachter N., Spigelman A., Side L., Zgajnar J., Mora J., Brewer C., Gadea N., Brady A.F., Gallagher D., Van Os T., Donaldson A., Stefansdottir V., Barwell J., James P.A., Murphy D., Friedman E., Nicolai N., Greenhalgh L., Obeid E., Murthy V., Copakova L., McGrath J., Teo S.-H., Strom S., Kast K., Leongamornlert D.A., Chamberlain A., Pope J., Newlin A.C., Aaronson N., Ardern-Jones A., Bangma C., Castro E., Dearnaley D., Eyfjord J., Falconer A., Foster C.S., Gronberg H., Hamdy F.C., Johannsson O., Khoo V., Lubinski J., Grindedal E.M., McKinley J., Shackleton K., Mitra A.V., Moynihan C., Rennert G., Suri M., Tricker K., Moss S., Kote-Jarai Z., Vickers A., Lilja H., Helfand B.T., Eeles R.A., Mikropoulos C., Selkirk C.G.H., Saya S., Bancroft E., Vertosick E., Dadaev T., Brendler C., Page E., Dias A., Evans D.G., Rothwell J., Maehle L., Axcrona K., Richardson K., Eccles D., Jensen T., Osther P.J., Van Asperen C.J., Vasen H., Kiemeney L.A., Ringelberg J., Cybulski C., Wokolorczyk D., Hart R., Glover W., Lam J., Taylor L., Salinas M., Feliubadalo L., Oldenburg R., Cremers R., Verhaegh G., Van Zelst-Stams W.A., Oosterwijk J.C., Cook J., Rosario D.J., Buys S.S., Conner T., Domchek S., Powers J., Ausems M.G., Teixeira M.R., Maia S., Schmutzler R., Rhiem K., Foulkes W.D., and Boshari T.

Abstract

Background:Prostate-specific antigen (PSA) and PSA-velocity (PSAV) have been used to identify men at risk of prostate cancer (PrCa). The IMPACT study is evaluating PSA screening in men with a known genetic predisposition to PrCa due to BRCA1/2 mutations. This analysis evaluates the utility of PSA and PSAV for identifying PrCa and high-grade disease in this cohort. Method(s):PSAV was calculated using logistic regression to determine if PSA or PSAV predicted the result of prostate biopsy (PB) in men with elevated PSA values. Cox regression was used to determine whether PSA or PSAV predicted PSA elevation in men with low PSAs. Interaction terms were included in the models to determine whether BRCA status influenced the predictiveness of PSA or PSAV. Result(s):1634 participants had 3/43 PSA readings of whom 174 underwent PB and 45 PrCas diagnosed. In men with PSA >3.0 ng ml -l, PSAV was not significantly associated with presence of cancer or high-grade disease. PSAV did not add to PSA for predicting time to an elevated PSA. When comparing BRCA1/2 carriers to non-carriers, we found a significant interaction between BRCA status and last PSA before biopsy (P=0.031) and BRCA2 status and PSAV (P=0.024). However, PSAV was not predictive of biopsy outcome in BRCA2 carriers. Conclusion(s):PSA is more strongly predictive of PrCa in BRCA carriers than non-carriers. We did not find evidence that PSAV aids decision-making for BRCA carriers over absolute PSA value alone.

Published
2018

32. Role of genetic testing for inherited prostate cancer risk: Philadelphia prostate cancer consensus conference 2017

Author

Giri, V.N. (Veda), Knudsen, K.E. (Karen E.), Kelly, W.K. (William K.), Abida, W. (Wassim), Andriole, G.L. (Gerald), Bangma, C.H. (Chris), Bekelman, J.E. (Justin E.), Benson, M.C. (Mitchell C.), Blanco, A. (Amie), Burnett, A. (Arthur), Catalona, W.J. (William J.), Cooney, K.A. (Kathleen A.), Cooperberg, M.R. (Matthew), Crawford, D. (David), Den, R.B. (Robert B.), Dicker, A.P. (Adam P.), Eggener, S. (Scott), Fleshner, N.E. (Neil), Freedman, M.L. (Matthew L.), Hamdy, F. (Freddie), Hoffman-Censits, J. (Jean), Hurwitz, M.D. (Mark D.), Hyatt, C. (Colette), Isaacs, W.B. (William B.), Kane, C.J. (Christopher J.), Kantoff, P. (Philip), Karnes, R.J. (Jeffrey), Karsh, L.I. (Lawrence I.), Klein, E.A. (Eric A.), Lin, D.W. (Daniel W.), Loughlin, K.R. (Kevin R.), Lu-Yao, G. (Grace), Malkowicz, S.B. (S. Bruce), Mann, M.J. (Mark J.), Mark, J.R. (James R.), McCue, P.A. (Peter A.), Miner, M.M. (Martin M.), Morgan, T. (Todd), Moul, J.W. (Judd W.), Myers, R.E. (Ronald E.), Nielsen, S.M. (Sarah M.), Obeid, E. (Elias), Pavlovich, C.P. (Christian P.), Peiper, S.C. (Stephen C.), Penson, D.F. (David F.), Petrylak, D.P. (Daniel P), Pettaway, C.A. (Curtis A.), Pilarski, R. (Robert), Pinto, P. (Peter), Poage, W. (Wendy), Raj, G.V. (Ganesh V.), Rebbeck, R. (Timothy), Robson, M. (Mark), Rosenberg, M.T. (Matt T.), Sandler, H. (Howard), Sartor, A.O. (Oliver), Schaeffer, E. (Edward), Schwartz, G.F. (Gordon F.), Shahin, M.S. (Mark S.), Shore, N.D. (Neal), Shuch, B. (Brian), Soule, H.R. (Howard R.), Tomlins, S.A. (Scott A), Trabulsi, E.J. (Edouard J.), Uzzo, R. (Robert), Griend, D.J.V. (Donald J. Vander), Walsh, P.C. (Patrick), Weil, C.J. (Carol J.), Wender, R. (Richard), Gomella, L.G. (Leonard G.), Giri, V.N. (Veda), Knudsen, K.E. (Karen E.), Kelly, W.K. (William K.), Abida, W. (Wassim), Andriole, G.L. (Gerald), Bangma, C.H. (Chris), Bekelman, J.E. (Justin E.), Benson, M.C. (Mitchell C.), Blanco, A. (Amie), Burnett, A. (Arthur), Catalona, W.J. (William J.), Cooney, K.A. (Kathleen A.), Cooperberg, M.R. (Matthew), Crawford, D. (David), Den, R.B. (Robert B.), Dicker, A.P. (Adam P.), Eggener, S. (Scott), Fleshner, N.E. (Neil), Freedman, M.L. (Matthew L.), Hamdy, F. (Freddie), Hoffman-Censits, J. (Jean), Hurwitz, M.D. (Mark D.), Hyatt, C. (Colette), Isaacs, W.B. (William B.), Kane, C.J. (Christopher J.), Kantoff, P. (Philip), Karnes, R.J. (Jeffrey), Karsh, L.I. (Lawrence I.), Klein, E.A. (Eric A.), Lin, D.W. (Daniel W.), Loughlin, K.R. (Kevin R.), Lu-Yao, G. (Grace), Malkowicz, S.B. (S. Bruce), Mann, M.J. (Mark J.), Mark, J.R. (James R.), McCue, P.A. (Peter A.), Miner, M.M. (Martin M.), Morgan, T. (Todd), Moul, J.W. (Judd W.), Myers, R.E. (Ronald E.), Nielsen, S.M. (Sarah M.), Obeid, E. (Elias), Pavlovich, C.P. (Christian P.), Peiper, S.C. (Stephen C.), Penson, D.F. (David F.), Petrylak, D.P. (Daniel P), Pettaway, C.A. (Curtis A.), Pilarski, R. (Robert), Pinto, P. (Peter), Poage, W. (Wendy), Raj, G.V. (Ganesh V.), Rebbeck, R. (Timothy), Robson, M. (Mark), Rosenberg, M.T. (Matt T.), Sandler, H. (Howard), Sartor, A.O. (Oliver), Schaeffer, E. (Edward), Schwartz, G.F. (Gordon F.), Shahin, M.S. (Mark S.), Shore, N.D. (Neal), Shuch, B. (Brian), Soule, H.R. (Howard R.), Tomlins, S.A. (Scott A), Trabulsi, E.J. (Edouard J.), Uzzo, R. (Robert), Griend, D.J.V. (Donald J. Vander), Walsh, P.C. (Patrick), Weil, C.J. (Carol J.), Wender, R. (Richard), and Gomella, L.G. (Leonard G.)

Abstract

Purpose: Guidelines are limited for genetic testing for prostate cancer (PCA). The goal of this conference was to develop an expert consensus-driv

Published
2018
Full Text
View/download PDF

33. Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition (vol 118, pg 266, 2018)

Author

Mikropoulos, C, Selkirk, CGH, Saya, S, Bancroft, E, Vertosick, E, Dadaev, T, Brendler, C, Page, E, Dias, A, Evans, DG, Rothwell, J, Maehle, L, Axcrona, K, Richardson, K, Eccles, D, Jensen, T, Osther, PJ, van Asperen, CJ, Vasen, H, Kiemeney, LA, Ringelberg, J, Cybulski, C, Wokolorczyk, D, Hart, R, Glover, W, Lam, J, Taylor, L, Salinas, M, Feliubadalo, L, Oldenburg, R, Cremers, R, Verhaegh, G, van Zelst-Stams, WA, Oosterwijk, JC, Cook, J, Rosario, DJ, Buys, SS, Conner, T, Domchek, S, Powers, J, Ausems, MGEM, Teixeira, MR, Maia, S, Izatt, L, Schmutzler, R, Rhiem, K, Foulkes, WD, Boshari, T, Davidson, R, Ruijs, M, Helderman-van den Enden, ATJM, Andrews, L, Walker, L, Snape, K, Henderson, A, Jobson, I, Lindeman, GJ, Liljegren, A, Harris, M, Adank, MA, Kirk, J, Taylor, A, Susman, R, Chen-Shtoyerman, R, Pachter, N, Spigelman, A, Side, L, Zgajnar, J, Mora, J, Brewer, C, Gadea, N, Brady, AF, Gallagher, D, van Os, T, Donaldson, A, Stefansdottir, V, Barwell, J, James, PA, Murphy, D, Friedman, E, Nicolai, N, Greenhalgh, L, Obeid, E, Murthy, V, Copakova, L, McGrath, J, Teo, S-H, Strom, S, Kast, K, Leongamornlert, DA, Chamberlain, A, Pope, J, Newlin, AC, Aaronson, N, Ardern-Jones, A, Bangma, C, Castro, E, Dearnaley, D, Eyfjord, J, Falconer, A, Foster, CS, Gronberg, H, Hamdy, FC, Johannsson, O, Khoo, V, Lubinski, J, Grindedal, EM, McKinley, J, Shackleton, K, Mitra, AV, Moynihan, C, Rennert, G, Suri, M, Tricker, K, Moss, S, Kote-Jarai, Z, Vickers, A, Lilja, H, Helfand, BT, Eeles, RA, Mikropoulos, C, Selkirk, CGH, Saya, S, Bancroft, E, Vertosick, E, Dadaev, T, Brendler, C, Page, E, Dias, A, Evans, DG, Rothwell, J, Maehle, L, Axcrona, K, Richardson, K, Eccles, D, Jensen, T, Osther, PJ, van Asperen, CJ, Vasen, H, Kiemeney, LA, Ringelberg, J, Cybulski, C, Wokolorczyk, D, Hart, R, Glover, W, Lam, J, Taylor, L, Salinas, M, Feliubadalo, L, Oldenburg, R, Cremers, R, Verhaegh, G, van Zelst-Stams, WA, Oosterwijk, JC, Cook, J, Rosario, DJ, Buys, SS, Conner, T, Domchek, S, Powers, J, Ausems, MGEM, Teixeira, MR, Maia, S, Izatt, L, Schmutzler, R, Rhiem, K, Foulkes, WD, Boshari, T, Davidson, R, Ruijs, M, Helderman-van den Enden, ATJM, Andrews, L, Walker, L, Snape, K, Henderson, A, Jobson, I, Lindeman, GJ, Liljegren, A, Harris, M, Adank, MA, Kirk, J, Taylor, A, Susman, R, Chen-Shtoyerman, R, Pachter, N, Spigelman, A, Side, L, Zgajnar, J, Mora, J, Brewer, C, Gadea, N, Brady, AF, Gallagher, D, van Os, T, Donaldson, A, Stefansdottir, V, Barwell, J, James, PA, Murphy, D, Friedman, E, Nicolai, N, Greenhalgh, L, Obeid, E, Murthy, V, Copakova, L, McGrath, J, Teo, S-H, Strom, S, Kast, K, Leongamornlert, DA, Chamberlain, A, Pope, J, Newlin, AC, Aaronson, N, Ardern-Jones, A, Bangma, C, Castro, E, Dearnaley, D, Eyfjord, J, Falconer, A, Foster, CS, Gronberg, H, Hamdy, FC, Johannsson, O, Khoo, V, Lubinski, J, Grindedal, EM, McKinley, J, Shackleton, K, Mitra, AV, Moynihan, C, Rennert, G, Suri, M, Tricker, K, Moss, S, Kote-Jarai, Z, Vickers, A, Lilja, H, Helfand, BT, and Eeles, RA

Abstract

This corrects the article DOI: 10.1038/bjc.2017.429.

Published
2018

34. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017

Author

Giri, VN, Knudsen, KE, Kelly, WK, Abida, W, Andriole, GL, Bangma, C.H., Bekelman, JE, Benson, MC, Blanco, A, Burnett, A, Catalona, WJ, Cooney, KA, Cooperberg, M, Crawford, DE, Den, RB, Dicker, AP, Eggener, S, Fleshner, N, Freedman, ML, Hamdy, FC, Hoffman-Censits, J, Hurwitz, MD, Hyatt, C, Isaacs, WB, Kane, CJ, Kantoff, P, Karnes, RJ, Karsh, LI, Klein, EA, Lin, DW, Loughlin, KR, Lu-Yao, G, Malkowicz, SB, Mann, MJ, Mark, JR, McCue, PA, Miner, MM, Morgan, T, Moul, JW, Myers, RE, Nielsen, SM, Obeid, E, Pavlovich, CP, Peiper, SC, Penson, DF, Petrylak, D, Pettaway, CA, Pilarski, R, Pinto, PA, Poage, W, Raj, GV, Rebbeck, TR, Robson, ME, Rosenberg, MT, Sandler, H, Sartor, O, Schaeffer, E, Schwartz, GF, Shahin, MS, Shore, ND, Shuch, B, Soule, HR, Tomlins, SA, Trabulsi, EJ, Uzzo, R, Griend, DJV, Walsh, PC, Weil, CJ, Wender, R, Gomella, LG, Giri, VN, Knudsen, KE, Kelly, WK, Abida, W, Andriole, GL, Bangma, C.H., Bekelman, JE, Benson, MC, Blanco, A, Burnett, A, Catalona, WJ, Cooney, KA, Cooperberg, M, Crawford, DE, Den, RB, Dicker, AP, Eggener, S, Fleshner, N, Freedman, ML, Hamdy, FC, Hoffman-Censits, J, Hurwitz, MD, Hyatt, C, Isaacs, WB, Kane, CJ, Kantoff, P, Karnes, RJ, Karsh, LI, Klein, EA, Lin, DW, Loughlin, KR, Lu-Yao, G, Malkowicz, SB, Mann, MJ, Mark, JR, McCue, PA, Miner, MM, Morgan, T, Moul, JW, Myers, RE, Nielsen, SM, Obeid, E, Pavlovich, CP, Peiper, SC, Penson, DF, Petrylak, D, Pettaway, CA, Pilarski, R, Pinto, PA, Poage, W, Raj, GV, Rebbeck, TR, Robson, ME, Rosenberg, MT, Sandler, H, Sartor, O, Schaeffer, E, Schwartz, GF, Shahin, MS, Shore, ND, Shuch, B, Soule, HR, Tomlins, SA, Trabulsi, EJ, Uzzo, R, Griend, DJV, Walsh, PC, Weil, CJ, Wender, R, and Gomella, LG

Published
2018

35. Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition

Author

Mikropoulos, C, Selkirk, CGH, Saya, S, Bancroft, E, Vertosick, E, Dadaev, T, Brendler, C, Page, E, Dias, A, Evans, DG, Rothwell, J, Maehle, L, Axcrona, K, Richardson, K, Eccles, D, Jensen, T, Osther, PJ, van Asperen, CJ, Vasen, H, Kiemeney, LA, Ringelberg, J, Cybulski, C, Wokolorczyk, D, Hart, R, Glover, W, Lam, J (Jan), Taylor, L, Salinas, M, Feliubadalo, L, Oldenburg, Rogier, Cremers, R, Verhaegh, G, van Zelst-Stams, WA, Oosterwijk, JC, Cook, J, Rosario, DJ, Buys, SS, Conner, T, Domchek, S, Powers, J, Ausems, M, Teixeira, MR, Maia, S, Izatt, L, Schmutzler, R, Rhiem, K, Foulkes, WD, Boshari, T, Davidson, R, Ruijs, M, Helderman-van d Enden, A, Andrews, L, Walker, L, Snape, K, Henderson, A, Jobson, I, Lindeman, GJ, Liljegren, A, Harris, M, Adank, MA (Muriel), Kirk, J, Taylor, A, Susman, R, Chen-Shtoyerman, R, Pachter, N, Spigelman, A, Side, L, Zgajnar, J, Mora, J, Brewer, C, Gadea, N, Brady, AF, Gallagher, D, Van Os, T, Donaldson, A, Stefansdottir, V, Barwell, J, James, PA, Murphy, D, Friedman, E, Nicolai, N, Greenhalgh, L, Obeid, E, Murthy, V, Copakova, L, McGrath, J, Teo, SH, Strom, S, Kast, K, Leongamornlert, DA, Chamberlain, A, Pope, J, Newlin, AC, Aaronson, N, Ardern-Jones, A, Bangma, C.H., Castro, E, Dearnaley, D, Eyfjord, J, Falconer, A, Foster, CS (Christopher), Gronberg, H, Hamdy, FC, Johannsson, O, Khoo, V, Lubinski, J, Grindedal, EM, McKinley, J, Shackleton, K, Mitra, AV, Moynihan, C, Rennert, G, Suri, M, Tricker, K, Moss, S, Kote-Jarai, Z, Vickers, A, Lilja, H, Helfand, BT, Eeles, RA, Mikropoulos, C, Selkirk, CGH, Saya, S, Bancroft, E, Vertosick, E, Dadaev, T, Brendler, C, Page, E, Dias, A, Evans, DG, Rothwell, J, Maehle, L, Axcrona, K, Richardson, K, Eccles, D, Jensen, T, Osther, PJ, van Asperen, CJ, Vasen, H, Kiemeney, LA, Ringelberg, J, Cybulski, C, Wokolorczyk, D, Hart, R, Glover, W, Lam, J (Jan), Taylor, L, Salinas, M, Feliubadalo, L, Oldenburg, Rogier, Cremers, R, Verhaegh, G, van Zelst-Stams, WA, Oosterwijk, JC, Cook, J, Rosario, DJ, Buys, SS, Conner, T, Domchek, S, Powers, J, Ausems, M, Teixeira, MR, Maia, S, Izatt, L, Schmutzler, R, Rhiem, K, Foulkes, WD, Boshari, T, Davidson, R, Ruijs, M, Helderman-van d Enden, A, Andrews, L, Walker, L, Snape, K, Henderson, A, Jobson, I, Lindeman, GJ, Liljegren, A, Harris, M, Adank, MA (Muriel), Kirk, J, Taylor, A, Susman, R, Chen-Shtoyerman, R, Pachter, N, Spigelman, A, Side, L, Zgajnar, J, Mora, J, Brewer, C, Gadea, N, Brady, AF, Gallagher, D, Van Os, T, Donaldson, A, Stefansdottir, V, Barwell, J, James, PA, Murphy, D, Friedman, E, Nicolai, N, Greenhalgh, L, Obeid, E, Murthy, V, Copakova, L, McGrath, J, Teo, SH, Strom, S, Kast, K, Leongamornlert, DA, Chamberlain, A, Pope, J, Newlin, AC, Aaronson, N, Ardern-Jones, A, Bangma, C.H., Castro, E, Dearnaley, D, Eyfjord, J, Falconer, A, Foster, CS (Christopher), Gronberg, H, Hamdy, FC, Johannsson, O, Khoo, V, Lubinski, J, Grindedal, EM, McKinley, J, Shackleton, K, Mitra, AV, Moynihan, C, Rennert, G, Suri, M, Tricker, K, Moss, S, Kote-Jarai, Z, Vickers, A, Lilja, H, Helfand, BT, and Eeles, RA

Published
2018

36. Assessment of Genetic and Immunological Factors Associated with Hepatitis C Infection in Saudi Hemodialysis Patients

Author

Amein K. Al-Ali, Samir H Al-Mueilo, Yazeed Al-Sheihk, Alhusain J. Alzahrani, Maaz Ulhasan, and Obeid E. Obeid

Subjects
education.field_of_study, biology, business.industry, medicine.medical_treatment, Hepatitis C virus, Population, Human leukocyte antigen, Hepatitis C, medicine.disease_cause, medicine.disease, Immunology, Genotype, biology.protein, Medicine, Hemodialysis, Antibody, business, education, Viral load
Abstract

The association of human leukocyte antigen (HLA) genotype and hepatitis C virus (HCV) infection has been reported in many populations. In addition, the HLA genotype distribution has been found to differ according to ethnicity. Currently, there are no published data concerning this relationship in the Saudi population. Therefore, the primary objective of this study was to determine the relationship between HLA genotype and HCV infection in a group of haemodialysis patients in a tertiary hospital in the Eastern Province of Saudi Arabia. A total of 152 haemodialysis patients and 160 controls were enrolled in the study. The patient group included 91 males and 61 females with a mean age of 48 years, who had been on haemodialysis for a period of 6 months to five years. The control group was randomly selected from donors attending the blood bank and included 155 males and five females with a mean age of 38 years. Of the patient group, 27 (17.8%) were found to have HCV antibodies by EIA. The seropositivity was confirmed by RIBA and by RT-PCR. The average viral load was 15 × 103 HCV RNA per 10 μl of plasma. The predominant HCV genotype was found to be genotype 4. HLA-class I and HLA class II were screened in 27 HCV-positive patients and in 30 age and sex matched controls by polymerase chain reaction/sequence specific primers (PCR/SSP) method. Measurements of cytokines Interleukin-2, 10, IFN-γ and TNFα showed that IL-2 level was 17.65 - 20.3 pg/l; IFN-γ was 22.15 - 41.1 pg/l; TNF-α was 2.5 - 5.6 pg/mL and IL-10 was 10.7 - 14.8 pg/mL. Measurement of CD markers showed the following: CD3 cells were measured. There was no correlation between infection with HCV and HLA type, cytokines levels and levels of different cell populations. CD markers are similar in the HCV-positive and HCV-negative hemodialysis patients. Further analysis and comparisons are needed, especially between the cytokines and CD markers in the hemodialysis patients and control groups.

Published
2014
Full Text
View/download PDF

39. Abstract P4-02-10: Breast cancer surveillance in high-risk women with dynamic contrast-enhanced magnetic resonance imaging every 6 months: Results from a single institution study

Author

Whitaker, K, primary, Guindalini, R, additional, Abe, H, additional, Sheeth, D, additional, Huo, D, additional, Hong, S, additional, Churpek, J, additional, Verp, M, additional, Obeid, E, additional, Zheng, Y, additional, Amico, A, additional, Yoshimatsu, T, additional, and Olopade, O, additional

Published
2018
Full Text
View/download PDF

41. Acute radiation oesophagitis associated with 2-deoxy-2-[18F]fluoro-d-glucose uptake on positron emission tomography/CT during chemo-radiation therapy in patients with non-small-cell lung cancer

Author

Everitt, S, Callahan, J, Obeid, E, Hicks, RJ, Mac Manus, M, Ball, D, Everitt, S, Callahan, J, Obeid, E, Hicks, RJ, Mac Manus, M, and Ball, D

Abstract

INTRODUCTION: Acute radiation oesophagitis (ARO) is frequently experienced by patients receiving concurrent chemo-radiation therapy (cCRT) for non-small-cell lung cancer (NSCLC). We investigated ARO symptoms (CTCAE v3.0), radiation dose and oesophageal FDG PET/CT uptake. METHOD: Candidates received cCRT (60 Gy, 2 Gy/fx) and sequential FDG PET/CT (baseline FDG0 , FDGwk2 and FDGwk4 ). Mean and maximum standardized uptake value (SUVmean and SUVmax) and radiation dose (Omean and Omax ) were calculated within the whole oesophagus and seven sub-regions (5-60 Gy). RESULTS: Forty-four patients underwent FDG0 and FDGwk2 , and 41 (93%) received FDGwk4 , resulting in 129 PET/CT scans for analysis. Of 29 (66%) patients with ≥ grade 2 ARO, SUVmax (mean ± SD) increased from FDG0 to FDGwk4 (3.06 ± 0.69 to 3.83 ± 1.27, P = 0.0019) and FDGwk2 to FDGwk4 (3.10 ± 0.75 to 3.83 ± 1.27, P = 0.0046). Radiation dose (mean ± SD) was higher in grade ≥2 patients; Omean (47.5 ± 20 vs 53.9 ± 10.2, P = 0.0061), Omax (13.7 ± 9.6 vs 20.1 ± 10.6, P = 0.0009) and V40 Gy (8.0 ± 8.2 vs 11.9 ± 7.3, P = 0.0185). CONCLUSIONS: FDGwk4 SUVmax and radiation dose were associated with ≥ grade 2 ARO. Compared to subjective assessments, future interim FDG PET/CT acquired for disease response assessment may also be utilized to objectively characterize ARO severity and image-guided oesophageal dose constraints.

Published
2017

42. Analysis of chemokines and soluble adhesion molecules in cytomegalovirus-positive renal transplant recipients

Author

Alhusain J. Alzahrani and Obeid E. Obeid

Subjects
Male, Nephrology, medicine.medical_specialty, Chemokine, Saudi Arabia, Congenital cytomegalovirus infection, Cytomegalovirus, Microbiology, Virology, Internal medicine, Prevalence, Humans, Medicine, Transplantation, biology, business.industry, virus diseases, General Medicine, medicine.disease, Kidney Transplantation, Infectious Diseases, Real-time polymerase chain reaction, Immunoglobulin M, Immunoglobulin G, Cytomegalovirus Infections, Immunology, biology.protein, Population study, Female, Parasitology, Chemokines, Antibody, Cytomegalovirus Positive, business, Cell Adhesion Molecules, Biomarkers
Abstract

Background: The relationship among cytomegalovirus (CMV) infection and the serum level of chemokines and soluble adhesion molecules is not well studied. This study aimed to assess chemokines and soluble adhesion molecules in CMV-positive Saudi renal transplant recipients. Methodology: The study was conducted in a tertiary hospital in Eastern Saudi Arabia over a 12-month period. All kidney transplant recipients who regularly attended the nephrology clinics were included (n = 150). Randomly selected age- and sex-matched individuals served as a control group (n = 158). CMV antibodies (IgG and IgM), chemokines and soluble adhesion molecules were measured using standard enzyme-linked immunosorbent assay (ELISA). CMV viral DNA was detected using real time polymerase chain reaction (PCR). Results: Of the 150 patients studied, 149 (n = 150) had detectable levels of Anti-CMV IgG antibodies (99.3%). In the control group, 113 (n = 158), blood donors had anti-CMV IgG antibodies (71.5%). Forty-one (n = 150) kidney transplant recipients were positive for anti-CMV IgM antibodies (27.3%), whereas only one (n = 158) blood donor had detectable anti-CMV IgM antibodies. All IgM positive samples contained CMV viral DNA. MCP-1, IL-8, ICAM-1, and VCAM-1 levels were measured using ELISA. Of those, only MCP-1 and IL-8 were detectable. Eighteen kidney transplant recipients were positive for MCP-1 (12%). All MCP-1 patients were also anti-CMV IgM positive, while 5 patients had detectable levels of IL-8 (3.3%). All these patients were CMV IgM-positive. Conclusions: The increase in chemokine levels during CMV infection may reflect a possible role for these molecules in the immunopathogenesis of CMV infection in this study population.

Published
2009
Full Text
View/download PDF

43. Molecular detection of hepatitis B, hepatitis C, and torque teno viruses in drug users in Saudi Arabia

Author

Obeid E. Obeid, Huda Bukhari, Ahmed A. Al-Qahtani, Alhusain J. Alzahrani, Damian M. Dela Cruz, and Mohammed N. Al-Ahdal

Subjects
Serum, Hepatitis B virus, Torque teno virus, Genotype, Hepatitis C virus, Hepacivirus, Saudi Arabia, Comorbidity, medicine.disease_cause, Drug Users, Flaviviridae, Virology, medicine, Humans, Substance Abuse, Intravenous, biology, business.industry, virus diseases, Hepatitis C, Hepatitis B, medicine.disease, biology.organism_classification, Hepatitis D, DNA Virus Infections, digestive system diseases, Infectious Diseases, business
Abstract

Injecting drug users are at increased risk of infection with hepatitis viruses and blood-borne pathogens. The aim of this study was to examine HBV, HCV, HDV, and TTV infections in Saudi drug users (N = 344). Extraction of nucleic acid from serum, reverse-transcription, amplification of viral nucleic acids, and HBV and HCV genotyping were done using established techniques. Of the analyzed samples, 41 (12%) contained detectable HBV DNA, 131 (38%) contained detectable HCV RNA, and 174 (51%) had detectable TTV DNA. The predominant HBV genotype was found to be genotype D and the predominant HCV genotype was found to be genotype 1b. All the samples were negative for HDV. Twelve samples (3.5%) were found to contain mixed HBV and HCV genomes, 24 samples (7%) were found to contain mixed HBV and TTV genomes, 82 samples (24%) were found to contain mixed HCV and TTV genomes, and 9 samples (2.6%) were found to contain mixed HBV, HCV, and TTV genomes. Identification of various infections in drug users will help the control of these infections in this group as well as in the community. J. Med. Virol. 81:1343–1347, 2009. © 2009 Wiley-Liss, Inc.

Published
2009
Full Text
View/download PDF

47. Lack of MERS Coronavirus Neutralizing Antibodies in Humans, Eastern Province, Saudi Arabia

Author

Obeid E. Obeid, Abdullah A Yousef, Stefanie Gierer, Heike Hofmann-Winkler, Stephanie Bertram, Amein K. Al-Ali, Stefan Pöhlmann, Waleed H. Albuali, Awatif N. Al-Nafaie, Abdullah M. Al-Rubaish, and Khaled R. Alkharsah

Subjects
Adult, Male, Microbiology (medical), Epidemiology, Middle East respiratory syndrome coronavirus, viruses, coronavirus, Saudi Arabia, lcsh:Medicine, Biology, Antibodies, Viral, medicine.disease_cause, lcsh:Infectious and parasitic diseases, Young Adult, respiratory infections, MERS-CoV, Seroepidemiologic Studies, medicine, Humans, Seroprevalence, neutralizing antibodies, lcsh:RC109-216, plasma, pseudotyping, Coronavirus, seroprevalence, lcsh:R, Dispatch, virus diseases, Spike Protein, spike, Middle Aged, Antibodies, Neutralizing, Virology, Infectious Diseases, biology.protein, Female, Antibody, Coronavirus Infections, serum, MERS coronavirus
Abstract

We used a lentiviral vector bearing the viral spike protein to detect neutralizing antibodies against Middle East respiratory syndrome coronavirus (MERS-CoV) in persons from the Eastern Province of Saudi Arabia. None of the 268 samples tested displayed neutralizing activity, which suggests that MERS-CoV infections in humans are infrequent in this province.

Published
2013
Full Text
View/download PDF

48. DETECTION OF HEPATITIS C VIRUS CORE ANTIGEN IN BLOOD DONORS USING A NEW ENZYME IMMUNOASSAY

Author

Alzahrani, Alhusain J. and Obeid, Obeid E.

Subjects
Hepatitis C virus, Core Antigen, virus diseases, Original Article, Blood Donors, ELISA, digestive system diseases
Abstract

Objectives: The purpose of the study was to evaluate the presence of hepatitis C virus [HCV] core antigen (HCV core Ag) in blood donors at King Fahd Hospital of the University, Al-Khobar, using the new HCV core Ag assay, and to correlate this finding with anti-HCV antibodies detected in the same samples using the standard Abbott MEIA(microparticle enzyme immunoassay). Materials and Methods: A total of 898 samples from blood donors were analyzed using the new assay prototype designed to detect and quantify total HCV core Ag in serum (Ortho-Clinical Diagnostics). Positive results were confirmed by the neutralization assay. The results of the HCV core Ag assay were compared with the results of the standard Abbott MIEA which measures anti-HCV antibody. Results and Conclusions: Out of the 898 samples tested, 18 samples were found to be positive by the HCV core Ag assay (2%). Out of these, 3 samples were confirmed positive by the neutralization protocol (0.33%). All the HCV core Ag positive samples were negative for anti-HCV antibodies (using MEIA by Abbott). These 3 donors may have been in the window period of HCV infection, or may be low responders for the HCV antigens, and are thus unable to mount detectable antibody level. The HCV core Ag assay is a potentially useful assay for screening blood donors, which will minimize the risk of using HCV positive blood from a patient in the window period of HCV infection.

Published
2004

49. Investigations of soot combustion on Yttria-Stabilized Zirconia by Environmental Transmission Electron Microscopy (ETEM)

Author

Aouine, M., Epicier, T., Obeid, E., Tsampas, M., Serve, A., PAJOT, K., Vernoux, P., AIR (AIR), Institut de recherches sur la catalyse et l'environnement de Lyon (IRCELYON), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC), IRCELYON, ProductionsScientifiques, Université de Lyon-Université de Lyon-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), and Université de Lyon-Université de Lyon-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)

Subjects
[CHIM.CATA] Chemical Sciences/Catalysis, [SDE.ES] Environmental Sciences/Environmental and Society, [CHIM.CATA]Chemical Sciences/Catalysis, [SDE.ES]Environmental Sciences/Environmental and Society
Abstract

International @ AIR+MAO:TEP:MTS:ASR:PVE; International audience; Investigations of soot combustion on Yttria-Stabilized Zirconia by Environmental Transmission Electron Microscopy (ETEM) M. Aouine1, T. Epicier1,2, E. Obeid1, M. Tsampas1, A. Serve1, K. Pajot3, P. Vernoux1* 1Université de Lyon, Institut de Recherches sur la Catalyse et l’Environnement de Lyon, UMR 5256, CNRS, Université C. Bernard Lyon 1, 2 avenue A. Einstein, 69626 Villeurbanne, France 2Université de Lyon, MATEIS, UMR 5510, CNRS, INSA de Lyon, 69621 Villeurbanne Cedex, France 3PSA PEUGEOT CITROËN, Centre technique de Vélizy, Route de Gisy 78943 Vélizy-Villacoublay, France *corresponding author:philippe.vernoux@ircelyon.univ-lyon1.fr Introduction Diesel Particulate Filters (DPFs) equip all Diesel light vehicles in Europe to remove toxic Particulate Matter (PM). They present high filtering efficiency (>99%) but must be periodically regenerated due to soot particles accumulation. In addition, from 2014, EURO 6 standards require the utilization of a NOx catalytic after-treatment device [1], preferentially placed between the Diesel Oxidation Catalyst (DOC) and the DPF [1]. Therefore, NO2 cannot anymore be utilized as an oxidant for soot combustion. This makes crucial the development of effective and durable catalysts for soot combustion with oxygen. We have recently reported that Yttria-stabilized Zirconia (YSZ), a pure oxygen ion ceramic conductor without any redox property, can continuously oxidize soot with oxygen in Diesel exhaust conditions [2]. It was proposed that the ignition of the soot oxidation on YSZ involves a fuel-cell-type electrochemical mechanism at the nanometric scale. Electrochemical oxidation of the soot could occur at the soot/YSZ interface while oxygen electrochemical reaction takes place at the triple phase boundary (tpb) soot/gas/YSZ. To get further insights of this mechanism, Environmental Transmission Electron Microscopy (ETEM) was used to in-situ follow the soot combustion at the interface with YSZ. Materials and Methods In situ, environmental experiments were performed in the Ly-EtTEM microscope, a last generation ETEM (TITAN 80-300 kV from FEITM) equipped with an aberration corrector. Pure oxygen was introduced owing to the high precision leaking valves at low pressure, up to typically 3 mbar. Samples prepared as a mixture of soot and YSZ particles (as described below) were deposited on titania grids with and without supporting film. These grids were subsequently mounted on a GatanTM heating stage in inconel; the temperature was raised up to typically 550°C. The microscope was operated at 80 and 300 kV. Soot was obtained from a mini Combustion Aerosol Standard (miniCAST, Jing Ltd. Switzerland) soot generator. The soot particles were produced with a mini-CAST burner from a propane/air flame. This mini-CAST soot shows an EC (Elemental Carbon) /TC (Total Carbon) ratio of ~0.95, closed to that reported in the literature for real Diesel soots [3]. Yttria-stabilized Zirconia (YSZ) powder, containing 8 mole % of Yttria from TOSOH, (ZrO2)0.92(Y2O3)0.08, was used as purchased. Collected soot and YSZ powder were mixed with a weight ratio of 1:4 and crushed for 20 minutes in a mortar in order to improve the soot/YSZ agglomerate contact, conventionally denoted as tight contact mode. Significance These in-situ ‘ETEM’ observations confirm that bulk YSZ oxygens are the active species for soot oxidation at the soot/YSZ interface. Acknowledgements We acknowledge the CLYM (Centre Lyonnais de Microscopie, www.clym.fr) for its guidance in the Ly-EtTEM project which was financially supported by the CNRS, the Région Rhône-Alpes, the ‘GrandLyon’ and the French Ministry of Research and Higher Education. The authors are grateful to the ANR (Agence National de la Recherche) for funding “PIREP2” project (N° ANR-2010-VPTT 006-01) and ADEME (Agence de l’Environnement et de la Maîtrise de l’Energie) for the PhD grants of E. Obeid and A. Serve. References 1B.A.A.L. van Setten, M. Makkee, J.A. Moulijn, Catalysis Reviews 2001, 43 (4), 489. 2.E. Obeid, L. Lizarraga, M.N. Tsampas, A. Cordier, A. Boréave, M.C. Steil, P. Vernoux, Journal of Catalysis 2014, 309, 87. 3.T. Ferge, E. Karg, A. Schroppel, K.R. Coffee, H.J. Tobias, M. Frank, E.E Gard, R. Zimmermann, Environmental Science & Technology 2006, 40 (10), 3327.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results